These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25996638)

  • 21. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.
    Bennette CS; Gallego CJ; Burke W; Jarvik GP; Veenstra DL
    Genet Med; 2015 Jul; 17(7):587-95. PubMed ID: 25394171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic testing in the European Union: does economic evaluation matter?
    Antoñanzas F; Rodríguez-Ibeas R; Hutter MF; Lorente R; Juárez C; Pinillos M
    Eur J Health Econ; 2012 Oct; 13(5):651-61. PubMed ID: 21598012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.
    Haverfield EV; Esplin ED; Aguilar SJ; Hatchell KE; Ormond KE; Hanson-Kahn A; Atwal PS; Macklin-Mantia S; Hines S; Sak CW; Tucker S; Bleyl SB; Hulick PJ; Gordon OK; Velsher L; Gu JYJ; Weissman SM; Kruisselbrink T; Abel C; Kettles M; Slavotinek A; Mendelsohn BA; Green RC; Aradhya S; Nussbaum RL
    BMC Med; 2021 Aug; 19(1):199. PubMed ID: 34404389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
    Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
    Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences].
    Shi JF; Mao AY; Bai YN; Liu GX; Liu CC; Wang H; Cao MM; Feng H; Wang L; Bai FZ; Huang HY; Bai HJ; Zhu J; Yan XX; Zhang J; Ren JS; Li N; Dai M; Chen WQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Mar; 54(3):306-313. PubMed ID: 32187937
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature.
    Smith HS; Swint JM; Lalani SR; Yamal JM; de Oliveira Otto MC; Castellanos S; Taylor A; Lee BH; Russell HV
    Genet Med; 2019 Jan; 21(1):3-16. PubMed ID: 29760485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the cost-effectiveness of child dental caries prevention programmes. Are we comparing apples and oranges?
    Anopa Y; Conway DI
    Evid Based Dent; 2020 Mar; 21(1):5-7. PubMed ID: 32221482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
    Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
    Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
    Ladabaum U; Wang G; Terdiman J; Blanco A; Kuppermann M; Boland CR; Ford J; Elkin E; Phillips KA
    Ann Intern Med; 2011 Jul; 155(2):69-79. PubMed ID: 21768580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
    Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A
    Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature.
    Skally M; Hanly P; Sharp L
    Appl Health Econ Health Policy; 2013 Jun; 11(3):181-92. PubMed ID: 23549792
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.